Skip to main content
. 2019 Nov 26;2019(11):CD009286. doi: 10.1002/14651858.CD009286.pub3

Yang 2011.

Methods Aim: to treat early post‐stroke depression
Participants Country: China
Setting: inpatient
Stroke: all pathological types, clinical diagnosis plus confirmation of lesion on imaging, no previous psychiatric and psychological disorders, age < 75 years old, stroke onset time < 72 hours, NIHSS score: 4 to 19
Mood: HAMD ≥ 8
Treatment: 20 people, mean age 64 ± 8 years, 8 men
Control: 22 people, mean age 64 ± 10 years, 13 men
Note inconsistency between abstract (20 in treatment and 22 in control, but in tables of results, there are 22 in treatment and 20 in control). We have used the data from the abstract
Excluded: functional psychiatric disorder, functional depression, psychoactive substance and addictive substance induced psychiatric disorders, infectious disease, severe cognitive impairment to affect communication, severe aphasia to affect communication, severe cardiac, pulmonary, hepatic and renal function impairment, previous organic brain disease such as brain tumour, or symptomatic stroke, encephalitis
Interventions Treatment: paroxetine 20 mg daily plus usual stroke care
Control: usual stroke care
Duration of treatment: at least 3 months
Duration of follow‐up: 0
Outcomes HAMD score, IL‐1β and IL‐6 level
Death
AEs not reported
Funding source Source of funding: local scientific academic fund
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "Case sequence" randomisation
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel (performance bias) 
 All outcomes High risk No placebo
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Not described
Incomplete outcome data (attrition bias) 
 All outcomes Low risk No dropouts
Selective reporting (reporting bias) Unclear risk No protocol
Other bias Low risk No difference in baseline